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A sequential test procedure for monitoring a singular 
safety and efficacy outcome 
 
Alan D. Hutson 





In this note we describe a modification of the sequential probability ratio test (SPRT) 
developed for the purpose of “flagging” a significant increase in the mortality rate of a 
treatment relative to a control while ensuring that double-blinding and the Type I error for the 
primary test of efficacy, also based on mortality rates, is not compromised. 
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Introduction 
 
Drug trials go through different phases.  In 
phase I trials the primary concern is safety, 
the subjects are typically healthy volunteer 
and patient studies, and the primary 
objective is to determine the maximum 
tolerated dose (MTD). This is followed by a 
phase II trial, which build upon the results of 
the phase I trial.   The primary goal of a 
phase II trial is to determine the optimal 
method of administration and examine 
potential efficacy. If the phase II trial 
demonstrates that the drug may be 
reasonably safe and potentially effective a 
phase III trial may be carried forth.  The 
primary goal of a phase III trial is to compare 
the effectiveness of the new treatment with 
that of existing treatments or placebo. 
 
In a majority of phase III clinical trials subject 
measurements can be divided into distinct 
efficacy and safety variables.  With the 
exception of truly sequential trials the 
primary efficacy variables are usually 
analyzed at a few well defined points in time 
(typically based upon calendar time or 
accrual milestones).  In contrast, safety is 
monitored continuously through the 
generation of adverse event (AE) reports to 
the respective internal review board (IRB) 
and review by the principal investigator (PI), 
with summary data safety monitoring board 
(DSMB) reports generated at regular 
intervals, e.g. quarterly or bi-yearly.  In a 
majority of high-risk clinical trials the DSMB 
will also monitor the flow of AE reports in 
real-time. 
 
In the specific case of double-blind controlled 
trials of a new treatment versus standard of 
care, or placebo, how might one monitor 
safety “continuously” and efficacy at distinct 
points in time when the primary safety and 
efficacy variable is mortality.  In addition, if 
the DSMB wishes to remain blinded to 
treatment assignment unless there is a true 
safety issue, what type of information is 
needed in order for them to make an 
informed decision in conjunction with real 
time monitoring of AE reports?  To generate 
a formal statistical rule to tackle this problem 
requires the principal investigators to design 
the trial around the efficacy outcome in the 
traditional sense, while the DSMB needs to 
determine what are the unacceptable 
differences between the new therapy and 
control in the opposite (unsafe) direction. 
 
In this note we develop a one-sided safety 
monitoring rule based upon a modification of 
Wald's classical sequential probability ratio 
test (SPRT)1.  This rule is to be used in 
conjunction with a randomized block design 
where the hypothesis involving efficacy is a 
simple comparison of two mortality 







. The general features of the safety 
monitoring procedure are as follows: 
 
1. Mortality can be evaluated within a fixed 
time period shortly following treatment, 
2. It is one-sided in the sense that a safety 
problem is not flagged if the new 
treatment appears efficacious, 
3. Requires the input of members of the 
DSMB to determine what an unsafe rate 
might be for the new therapy relative to 
control given the design parameters of 
the trial, 
4. Is continuously sequential in terms of 
blocks of subjects being the unit of time, 
5. It is easily explained to non-statisticians 
through the use of examples, 
6. Maintains the Type I error control for the 
test of efficacy conditioned upon the 
relative safety of the experimental 
therapy. 
 
The motivation of this methodology stemmed 
from the request of our DSMB to generate a 
safety monitoring rule based upon statistical 
methods for the DCA-MALA clinical trial of 
malaria in Ghana2.  This trial was designed 
as a randomized, double-blind, placebo-
controlled single-center trial. The trial was 
originally designed to enroll n=1500 
subjects, but was terminated earlier due to 
financial reasons. For this specific trial of 
dichloroacetate (DCA) versus placebo the 
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measure of efficacy was 28-day mortality, 
and the primary measure of safety was also 
28-day mortality.  Ultimately the DSMB 
wanted a simple statement after each block 
of subjects completed the trial:  “remain 
blinded at this point in time” or that the “blind 
be broken at this point in time.”  Unblinding 
the study is used to mean group summary 
statistics will be analyzed and presented in 
an unblinded fashion.  This does not 
necessarily mean that data at the individual 
subject level is unblinded.  Also note that the 
principal investigators would remain blinded 
even if the DSMB were to take an unblinded 
look at this trial.  The use of this rule still 
allowed us to monitor secondary measures 
of safety in the standard way3-4.  In addition, 
adverse events involving mortality were still 





We will employ a version of a sequential test 
for the purpose of generating a safety 
monitoring rule, which will basically flag a 
problem for the DSMB with respect to a 
disproportionate amount of mortalities for a 
new therapy relative to the standard of care 
or placebo. Note that this rule does not 
terminate the clinical trial, it only suggests 
unblinding the trial for the purpose of more 
intense scrutiny.  The sequential test is 
based upon a modification of the SPRT, 
initially developed by Wald1, and is a 
procedure for testing a simple null 
hypothesis versus a simple alternative 
hypothesis continuously in time.  With 
respect to the new safety monitoring plan, 
“continuously in time” will refer to blocks of 
subjects who complete the trial as opposed 
to testing after individual subjects complete 
the trial.  Therefore, in order to implement 
this rule effectively the design of the trial 
should be of the form of a randomized block 




denote the total number 
of subjects for the new treatment plus the 







 denote the number of 




For the purposes of our safety monitoring 
plan we set the null “efficacy” hypothesis to 
correspond to the original study design and 
the alternative “safety” hypothesis to 
correspond to unsafe rates of the new 





denote the event rates of the new therapy 
and control group, respectively.   Then the 
safety data monitoring rule(SDMR) consists 
of testing  
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 subjects complete 
the study.  The DSMB chairperson is then 
notified of the results after each test is 
carried out per block.  We strongly 





corresponding to H0 be chosen based upon 
the original study design pertaining to 
efficacy.  For example, in the DCA-MALA 
trial the mortality rates from which the trial 
was designed were p
1 
= 0.19 and p
2
=0.25, 
for DCA and placebo, respectively.  For H
1
, 
the “safety” hypothesis, the DSMB with the 
guidance of a simulation study deemed 
p
1
=0.28 to be an unacceptable death rate in 
the DCA arm given a placebo death rate of 
p
2
=0.25, and accounting for statistical noise.  
The mathematical details for the efficacy and 
safety “functions” are contained in Appendix 
A.  Through simulations we illustrated that if 
the placebo death rate is lower than 
anticipated the decision to recommend 
unblinding the trial will be earlier given the 





=0.15 for DCA 
relative to placebo. Note that the unblinding 
rule can be easily modified to accommodate 
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where i=1, 2,···, K, and again K denotes the 
number of blocks.  The safety monitoring test 
statistic 
i





2ip  updated after every block i.  For 





=10 based upon efficacy considera-




 have to be large 
enough to produce a meaningful value for 
i
. 
The details for the calculation of 
i
 are 
contained in Appendix A.  If 
i
 A then stop 
and reject H0 (recommend unblinding the 
study). If 
i
 B then stop and accept H0 
(reset the monitoring rule), else continue to 
monitor the safety of the study. The 
consequences of resetting the monitoring 
rule are examined further in Section. 
 
Classical statistical theory dictates that A ≤  
β
α−1




 .  The crude stopping 
bounds A = 
β
α−1




 work well 
for our purpose.  This is demonstrated via 
the the simulation study in Section 3.  The 
parameters  and  correspond roughly to 
traditional fixed sample size Type I and Type 
II error rates.  Hence, we will typically 
choose  to be much smaller than  if the 
primary goal is safety monitoring. For the 
DCA-MALA trial we determined that the 
appropriate levels would be to set =0.20 
and =10-8 such that it would be unlikely that 
the test terminates earlier and we accept H0, 
yet the test would terminate quickly if there is 
a safety concern.  Setting =0.20 and =10-8 
corresponds to the stopping bounds of 
A=9.9999 and B=0.00001.  Therefore, if the 
test errs it will err on the conservative side in 
terms of unblinding the study early.  The 
parameters  and  may be adjusted by the 
DSMB in order to relax or tighten the 
monitoring rule during the course of the 
study. 
 
Using the candidate choices of =0.20 and 
=10-8 (approximately null) in the DCA-
MALA trial it was determined through 
simulation that 
i
 would never be less than B 
prior to the first planned interim analysis at 
50% accrual.  If this scenario did occur it 
would have indicated that DCA is 
substantially more effective than originally 
anticipated and that the safety of DCA in 
terms of the mortality rates shouldn't be of 
concern to the EAC at that current point in 
time.  Therefore, we propose that if 
i
 <B 
during any point in the study that the SPRT 
decision rule be reset at block i-1, i.e. restart 
the safety monitoring rule one block back 
relative to the current point in time (block i) 
as the new “time 0.”  This provides a one 
block “burn-in” period to reset the rule.  Even 
after resetting the test statistic due to the 
outstanding performance of the new therapy, 
a short run of deaths could occur favoring 
control such that  reverses its path and 
crosses A.  This rare event (given a long-
term past history of treatment efficacy) would 
not stop the trial, however, the 
recommendation to unblind the trial at that 
point in time would be made to the DSMB 
Chair.  It would then have to be determined 
whether this run was due to chance alone, or 
some deterministic cause such as a bad 




The following simulation study is used to 
illustrate the proportion of times out of 
10,000 simulations that the decision to 
“remain blinded”or “unblind the study” would 
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occur over possible choices of 
=0.05,0.10,0.20 and =10-7, 0.05, 0.10 for a 
clinical trial with sample size fixed at n=1500, 
broken into K=75 blocks.  The decision to 
“reset the trial” the trial, as described above, 
is built-in to the simulation study.  The 
numbers are similar to the operating 
characteristics of the DCA-MALA trial, 
however, there are no planned interim 
analyses.  In addition, the median time that  
crosses A or B is given. For any specific trial 
of interest a similar simulation study should 
be undertaken in order to determine the 
appropriate parameter values for  and . 
 
In this specific simulation study the efficacy 
hypothesis 0(p1,p2) was fixed at 0(0.20, 
0.25) as determined by a hypothetical trial 
design.  Assume that the DSMB decided the 
safety hypothesis should be 
1
 (0.30, 0.25).  
The simulations were then carried out given 









) were set to 
(0.15,0.25), (0.20,0.25), (0.25,0.25), 
(0.30,0.25), (0.20,0.15), and (0.15,0.10), 
corresponding to the new treatment being 
more efficacious than planned, the new 
treatment being efficacious as planned, the 
new treatment being equivalent to placebo, 
the new treatment being worse than placebo 
at the correct placebo rate,  the new 
treatment being worse than placebo at a 
lower placebo mortality rate,  and the new 
treatment being worse than placebo at a 
very low and unexpected placebo mortality 
rate, respectively. 
 
The simulation results are provided in Tables 
1-9.  Since we are primarily interested in 
testing for safety the choice of  and  
comes down to a tradeoff between stopping 
times and Type I error for this application. 
The column labeled “Median Sample Size” 
indicates the median time at which a 
decision rule is to be implemented if the true 




.  If 
we were confident of the underlying truth 




 in terms of efficacy 
then it becomes a question of trade-offs.  
Table 1:  Simulation Results 
 
















0.15 0.25 1500 0.5% 95.5% 
0.20 0.25 1500 6.3% 93.7% 
0.25 0.25 1240 54.4.0% 45.6% 
0.30 0.25 340 97.6% 2.4% 
0.20 0.15 280 99.2% 0.8% 
0.15 0.10 240 99.8% 0.2% 
 
Table 2:  Simulation Results 
 
















0.15 0.25 1500 1.3% 98.7% 
0.20 0.25 1500 11.2% 88.8% 
0.25 0.25 800 63.6% 36.4% 
0.30 0.25 260 98.5% 1.5% 
0.20 0.15 200 99.5% 0.5% 
0.15 0.10 180 99.9% 0.1% 
 
Table 3:  Simulation Results 
 
















0.15 0.25 1500 3.6% 96.4% 
0.20 0.25 1500 19.8% 80.2% 
0.25 0.25 440 72.8% 27.2% 
0.30 0.25 180 99.2% 0.8% 
0.20 0.15 140 99.7% 0.3% 
0.15 0.10 120 99.6% 0.4% 
 
Table 4:  Simulation Results 
 
















0.15 0.25 1500 0.4% 99.6% 
0.20 0.25 1500 6.7% 93.7% 
0.25 0.25 1220 54.8% 45.2% 
0.30 0.25 320 97.6% 2.4% 
0.20 0.15 260 99.2% 0.8% 
0.15 0.10 240 99.6% 0.6% 
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What safety error rate is the DSMB willing to 
live with. For example from Table 1, if the 
DSMB chose =0.05 and =10-7 then we 
would indicate to the DSMB that they would 
likely “unblind” the trial early 6.3% of the time 
over theoretical repetitions of the study, and 
“unblind” the trial early 97.6% of the time if 
there was a true safety concern.   Note that if 
the new treatment was more successful than 
anticipated the “unblinding rate” goes down 
to 0.5%.  If the DSMB wanted a very 
stringent rule then they might go with =0.2 
and =10-7, e.g. see Table 3.  A possible 
tradeoff would be to choose =0.1 and =0.1 
in Table 8, where we would unblind the study 
at rate 12.3% if we were close to the 
proportions from which the study was 
planned around, and unblind the study 
98.9% of the time if we were close to the 
safety hypothesis. 
 
DCA-MALA Trial Example 
 
The following text appeared(modified slightly 
for this paper) in each  DCA-MALA DSMB 
report following the adoption of the 
sequential test called the safety decision 
monitoring rule(SDMR) in the DCA-MALA 
trial. “After every 20 subjects (one 
randomization blocking unit) have completed 
the study the biostatistics coordinating center 
will “update” the SDMR and recommend to 
the DSMB to either remain blinded to the 
treatment assignment or to unblind the 
treatment assignment due to a significant 
increase in the mortality rate, beyond 
random noise, of the DCA group relative to 
Table 5:  Simulation Results 
 
















0.15 0.25 1500 1.2% 98.8% 
0.20 0.25 1500 12.2% 87.8% 
0.25 0.25 760 64.1% 35.9% 
0.30 0.25 240 98.4% 1.6% 
0.20 0.15 200 99.5% 0.5% 
0.15 0.10 180 99.8% 0.2% 
 
Table 6:  Simulation Results 
 
















0.15 0.25 1500 4.0% 96.0% 
0.20 0.25 1500 21.2% 78.8% 
0.25 0.25 740 73.2% 26.8% 
0.30 0.25 160 99.2% 0.8% 
0.20 0.15 140 99.7% 0.3% 
0.15 0.10 120 99.9% 0.1% 
 
Table 7:  Simulation Results 
 
















0.15 0.25 1500 0.4% 99.6% 
0.20 0.25 1500 7.1% 92.9% 
0.25 0.25 1120 56.3% 43.7% 
0.30 0.25 320 97.8% 2.2% 
0.20 0.15 260 99.0% 1.0% 
0.15 0.10 240 99.6% 0.4% 
 
Table 8:  Simulation Results 
 
















0.15 0.25 1500 1.6% 98.4% 
0.20 0.25 1500 12.3% 87.8% 
0.25 0.25 740 65.3% 34.7% 
0.30 0.25 240 98.9% 1.1% 
0.20 0.15 200 99.6% 0.4% 
0.15 0.10 180 99.8% 0.2% 
 
Table 9:  Simulation Results 
 
















0.15 0.25 1500 4.4% 95.6% 
0.20 0.25 1500 21.3% 78.7% 
0.25 0.25 380 74.3% 25.7% 
0.30 0.25 160 99.2% 0.8% 
0.20 0.15 140 99.7% 0.3% 
0.15 0.10 120 99.9% 0.1% 
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the placebo group.  In addition to the SDMR, 
mortality data will always be monitored on 
case-by-case basis, i.e. if a sequential series 
of anomalous deaths occur in any given 
block the DSMB will be notified immediately, 
regardless of the SDMR”.  
 
The original trial was designed to enroll 
n=1500 subjects if accrual through two 
interim analysis reached 100%.  
Unfortunately, the trial was terminated early 
after only n=123 subjects had completed the 
study due to problems stemming from failing 
to meet accrual milestones set by the 
sponsors.  The low accrual rates were 
directly related to unusual dry spells 
occurring during the rainy seasons when 
malaria is prevalent. However, there was 
enough data gathered in order to 
demonstrate how the SDMR rule works in 
reality. 
 
In order to illustrate the new SDMR to the 
DCA-MALA DSMB prior to their approval or 
disapproval, the following examples were 
presented to the committee members. The 
method was illustrated using various “made-
up” outcomes, which were similar to what we 
anticipated might possibly occur during the 
DCA-MALA trial given 







 = .28, p
2
 = .25),   
 
The results are presented in Tables 10 – 14.  
After every N
i
 =10+10 subjects completed 
the study 
i
 was calculated along with the 
corresponding recommendation:  “Remain 
Blinded” or “Unblind the Study.”  The 
example given in Table 14 is the only case 
where DCA mortality was consistently lower 
than placebo mortality and hence the 
decision was always to “Remain Blinded.”  In 
all other examples the decision to unblind 
the study was a function of the true 
underlying mortality rates.  In our opinion 
these simple examples provided to the 
committee helped illustrate the utility of the 
SDMR and thus they ultimately endorsed its 
implementation. 
Results for the DCA-MALA Trial 
 
In this section we illustrate how the SPRT 
decision rule worked within the context of the 
DCA-MALA trial through 120 subjects given 
=0.20 and =10-8 corresponding to 
boundaries of A=9.9999999 and 
B=0.0000111.  The trial was terminated due 
to financial circumstances after n=123 
subjects were enrolled. Hence, the final 3 
subject’s data were not included in the safety 
monitoring statistic illustrated here.  
Let 
^
1p  and 
^
2p denote the estimated 
mortality rates in the DCA and placebo 
treatment groups for each block of 20 
subjects. As can be seen the value of 
i
 
started to “drift” toward A=9.9999999 as the 
imbalance in mortality rates favored DCA 
and then started to “drift” back towards 
B=0.0000111 as the mortality rates became 
more balanced.  The simplicity of 
programming this method is illustrated via 
the SAS program used to carry out the 




In this note we presented a statistical 
decision rule for data safety monitoring 
purposes when the primary efficacy and 
primary safety endpoint of a clinical trial is 
mortality. This rule was designed for ease of 
interpretation by DSMB members with little 
or no formal statistical training.  The goal of 
this method is to provide a means of 
controlling the approximate Type I error 
control for the efficacy analysis, while 
monitoring safety in a continuous fashion. As 
was discussed above, the method may be 
modified to accommodate more complex 
designs.  Future work will involve studying 
the probability theory behind the utilization of 
different sequential bounds for efficacy and 
safety such this information can be 
incorporated into the sample size 
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 denote the true underlying mortality rates 
in the DCA and placebo treatment groups, respectively.  
For our application we have developed a modified 
SPRT statistical decision rule which will test the 
following simple hypotheses after every 20 subjects 
have been enrolled, namely, 
H0 : 0 = arcsin 1p  - arcsin 2p , 
 















20 2 2 Remain Blinded 
40 3 2 Remain Blinded 
60 4 0 Unblind the study 
    














20 4 2 Remain Blinded 
40 4 2 Remain Blinded 
60 4 2 Remain Blinded 
80 4 2 Unblind the study 
 














20 3 2 Remain Blinded 
40 3 2 Remain Blinded 
60 3 2 Remain Blinded 
80 3 2 Remain Blinded 
100 3 2 Remain Blinded 
120 3 2 Unblind the Study 
 














20 1 2 Remain Blinded 
40 1 2 Remain Blinded 
60 1 2 Remain Blinded 
80 8 2 Remain Blinded 
100 1 2 Remain Blinded 
120 8 2 Unblind the study 
 














20 1 2 Remain Blinded 
40 1 2 Remain Blinded 
60 1 2 Remain Blinded 
80 1 2 Remain Blinded 
100 1 2 Remain Blinded 
120 1 2 Remain Blinded 
140 1 2 Remain Blinded 
160 1 2 Remain Blinded 
180 1 2 Remain Blinded 
200 1 2 Remain Blinded 
220 1 2 Remain Blinded 
 













1 1.40995 remain blinded 0.2 0.1 
2 2.91669 remain blinded 0.1 0.0 
3 3.89147 remain blinded 0.3 0.2 
4 2.04235 remain blinded 0.0 0.1 
5 2.12806 remain blinded 0.2 0.2 
6 1.11686 remain blinded 0.0 0.1 
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 = arcsin 1p  - arcsin 2p . 
 




 were chosen based upon the 
original study design. 
Test Statistic. Let  
^
1p  = ( mortalities in the DCA 
arm/n
1i
) and  
^





 denotes the number of subjects per 
block i on  DCA and  n
2i
 denotes the number of subjects 





=10.  Even though the sample size per block is 
relatively small, the following asymptotic distributional 


























































which will  be monitored continuously in time as defined 
by block i.  It is easily shown that z
i 
~ AN(j,1), where 
the distribution of z
i
 will be denoted ( )izf jθ , under Hj, 
j=0,1, respectively.  Based upon ( )izf jθ   the  SPRT 
test decision rule now follows straightforward from the 









θλ =          (A.4) 





)(θ  and m = 1,2···, 
denotes the  current block. If 
i
 > A then stop and reject 
H0.  If i <B then stop and accept H0, else continue to 









Appendix B: SDMR SAS Program 
 
proc format; 
value dform 0=’nblind’ 
            1='recalculate' 
            2='remain blinded'; 
data simul; 












data check;set simul; 
retain f0 f1; 
label p1='DCA death rate' 





hp1=.19;    /*active under null*/ 
hp11=.28;   /*active under alternative*/ 
















  pi=2*arcos(0); 
  f0=f0*exp(-z0*z0/2)/sqrt(2 *pi*(1/(4*n1)+1/(4*n2))); 
  f1=f1*exp(-z1*z1/2)/sqrt(2 *pi*(1/(4*n1)+1/(4*n2))); 
  lambda=f1/f0; 
  a=(1-beta)/alpha;b=beta/(1-alpha); 
  dec=2; 
  if lambda>a then dec=0; 
  if lambda<b then dec=1; 
format dec dform.; 
 
proc print; 
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